MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    Assessment of Gait in Huntington’s disease patients using EncephaLog smartphone’s application

    NI. Inbar, N. Omer, A. Bar David, N. Geva, I. Dabakarov, L. Barsky, Z. Yekutieli, N. Giladi, T. Gurevich (Tel Aviv, Israel)

    Objective: Huntington’s disease (HD) patients cope with unique gait disturbances. Proper evaluation of gait in these patients is highly needed. Dyskinesia may negatively affect validity…
  • 2019 International Congress

    Impact of caring for patients with Huntington’s disease on work status

    K. Raimundo, R. Tan, T. To, J. de Courcy, U. Ondhia, H. Rickards, M. Nance (San Francisco, CA, USA)

    Objective: To describe changes in the employment status of family members caring for a person with Huntington’s disease (HD) in the US and Europe. Background:…
  • 2019 International Congress

    Involuntary movements with abnormal brain imaging: A Case Report

    W. Webb, P. Chapman, V. Sung, M. Dean (Birmingham, AL, USA)

    Objective: To present a case of juvenile-onset Huntington's disease (HD) with a mixed phenotype and abnormal brain imaging. Background: HD is an autosomal-dominant neurodegenerative disorder…
  • 2019 International Congress

    Effects of Cognitively Challenging Agility Exercise Program on Clinical and Objective Measures in People with Parkinson’s Disease

    P. Carlson-Kuhta, N. Hasegawa, SH. Jung, V. Shah, A. Ragothaman, D. Peterson, K. Smulders, L. King, M. Mancini, J. Lapidus, J. Nutt, F. Horak (Portland, OR, USA)

    Objective: To investigate the effects of a 6-week cognitively challenging exercise intervention in people with Parkinson’s disease (PD). Background: Gait and balance impairments have been…
  • 2019 International Congress

    Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study

    M. Facheris, J. Benesh, J. Streit, W. Robieson, C. Zadikoff, D. Standaert (North Chicago, IL, USA)

    Objective: To assess the local and systemic safety and tolerability of ABBV-951 delivered as a continuous subcutaneous infusion (CSCI) for 24 hours daily for up…
  • 2019 International Congress

    Open-label safety and tolerability of L-Dihydroxyphenylserine (L-DOPS) and high dose carbidopa therapy in Parkinson’s disease patients

    K. Hay, K. Mcdonell, P. Trujillo, M. Donahue, N. van Wouwe, D. Claassen (Nashville, TN, USA)

    Objective: To assess safety, tolerability, and central effects of L-Dihydroxyphenylserine (L-DOPS), in Parkinson’s disease (PD) patients treated with DOPA decarboxylase inhibition. Background: Norepinephrine (NE) is…
  • 2019 International Congress

    Development Of Anti-Parkinsonism Poly Herbal Sustained Release Formulation Composed Of Potential Traditional Plant Extracts

    S. Jain, A. Jain, S. Bhargav (Sagar, India)

    Objective: Parkinsonism is one of the commonest neurodegenerative diseases, which is characterized by a selective and progressive degeneration of dopaminergic neurons, causing a series of…
  • 2019 International Congress

    Opicapone and levodopa-carbidopa intestinal gel infusion: a cost saving analysis in the United Kingdom

    V. Leta, D. van Wamelen, A. Sauerbier, S. Jones, A. Podlewska, D. Trivedi, M. Parry, P. Odin, A. Storch, Z. Pirtošek, A. Antonini, K. Ray Chaudhuri (London, United Kingdom)

    Objective: To investigate whether the use of Opicapone as an add-on therapy to levodopa-carbidopa intestinal gel (LCIG) infusion in advanced Parkinson’s disease (PD) reduces the…
  • 2019 International Congress

    Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions

    C. Marse, J. Benoit, F. Rocher, C. Giordana (Nice, France)

    Objective: Report a case of extensive cutaneous necrosis due to apomorphine treatment with fatal outcome. Background: Subcutaneous (SC) apomorphine is used as a treatment of…
  • 2019 International Congress

    Evaluating the real-world effectiveness of carbidopa/levodopa enteral suspension (CLES) on patients with advanced Parkinson’s disease in USA: Interim-evidence from the PROviDE study

    R. Pahwa, S. Isaacson, P. Kandukuri, Y. Jalundhwala, P. Kukreja, Y. Bao, N. Gupta, I. Pan, J. Aldred (Kansas City, KS, USA)

    Objective: To evaluate the real-world effectiveness of carbidopa/levodopa enteral suspension (CLES) in patients with advanced Parkinson’s disease (PD) in real world at home setting in…
  • « Previous Page
  • 1
  • …
  • 189
  • 190
  • 191
  • 192
  • 193
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley